TScan Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $27.32M
- P/E (TTM)
- –
- Dividend yield
- –
About TScan Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a clinical-stage biotechnology firm that develops T cell receptor-engineered T cell therapies to treat cancer and autoimmune conditions. Its primary clinical focus is on hematologic malignancies, led by candidate TSC-101 for patients with acute myeloid leukemia and myelodysplastic syndrome receiving allogeneic hematopoietic cell transplantation. The company is also developing candidates TSC-102-A01 and TSC-102-A03 targeting CD45, as well as preclinical in vivo multiplex therapies for solid tumors. In autoimmune indications, it discovers targets for conditions such as ankylosing spondylitis, ulcerative colitis, and Crohn's disease. Its potential end customers are patients suffering from these cancers and immune-mediated disorders.
The company operates an internal good manufacturing practices facility to produce clinical supply and collaborates with a global contract development and manufacturing organization with commercial capabilities. In addition, it conducts a multi-center clinical trial with more than 20 activated clinical sites across the United States. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of TScan Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TScan Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 830 Winter Street 02451
- Phone
- (857) 399-9500
- Employees
- 142, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- TCRX
- Exchange
- Nasdaq
- IPO date
- Jul 19, 2021
- Shares outstanding
- 68M, Aug 7, 2026
- Public float
- $56.87M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1783328
- CUSIP
- 89854M101
- ISIN
- US89854M1018
- EIN
- 82-5282075
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gavin MacBeath | Chief Executive Officer, Director | 49,767 |
| Jason Amello | Chief Financial Officer | – |
| Zoran Zdraveski | See Remarks | 67,111 |
| Chrystal Louis | Chief Medical Officer | – |
| Leiden Dworak | See Remarks | 5,692 |
| Bros. Advisors (GP) LLC Baker | Director | – |
| Keith Woods | Director | – |
| 667, L.P. | Director | 256,209 |
| Katina Dorton | Director | – |
| Garry A. Nicholson | Director | – |
| Gabriela Gruia | Director | – |
| Barbara Klencke | Director | 70,000 |
| Bros. Advisors Lp Baker | Director | – |
| Julian Baker | Director | – |
| Felix Baker | Director | – |
| Brothers Life Sciences LP Baker | Director | – |
Employees
Headcount reported in annual reports
“As of February 27, 2026, we had 142 full-time employees and 0 part-time employees, 29 of whom have Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 2, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 19, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 13, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |